DEFINING TOMORROW'S VASCULAR STRATEGIES
×
Register now to R3i !
Become a member to receive our newsletter and get unrestricted access to downloadable slidekits...
Your login
Your password
Confirm your password
Your email
I agree to receive the R3i newsletter
The Initiative

Prof. Nikolaus Marx

Prof. Nikolaus Marx
University of Aachen,
Aachen, Germany
 
Current position
 
2009 Head of Medicine Department I, Cardiology, Pneumology, and Angiology
University Clinic, Aachen
 
Scientific training
 
1994 MD - Universities of Mainz, Genf (Switzerland) and Düsseldorf (Germany)
  Post-doctoral fellowship - Brigham and Women's Hospital, Harvard Medical School, USA
  Board-certified internist - University of Ulm
  Board-certified cardiologist - University of Ulm
  Board-certified specialist for intensive care medicine in internal medicine - University of Ulm
 
Professional Associations
 
  Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (DGK)
  Deutsche Stiftung für Herzforschung
  Deutsche Gesellschaft für Arterioskleroseforschung
  European Society of Cardiology (ESC)
  American Heart Association (AHA)
  Deutsche Diabetes Gesellschaft (DDG)
  European Association for the Study of Diabetes (EASD)
  German Diabetes Association
  Assistant Editor for Diabetes and Vascular Disease Research
 
Awards
 
1999 Servier Young Investigators Award -  First European Meeting on Vascular Biology and Medicine
2002 Winner of the Poster Award Competition in Epidemiological Science - AHA
2004 Morgagni Young Investigator Award
2005 The Rising Star Award -  European Association for the Study of Diabetes (EASD)
 
Publications (selection)
 
  • Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W: The antidiabetic PPAR alfa-activator rosiglitazone reduces MMP-9 serum levels in type-2 diabetic patients with coronary artery disease. Arterioscl Thromb Vasc Biol 2003; 23:283-288
  • Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, März W, Hombach V, Koenig W: Effect of rosiglitazone treatment on soluble CD40L in type-2 diabetic patients with coronary artery disease. Circulation 2003; 107:1954-1957
  • Marx N, Walcher D, Raichle C, Aleksic M, Bach H, Grüb M, Hombach V, Libby P, Zieske A, Homma S, Strong J: C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscl Thromb Vasc Biol 2004; 24:540-545
  • Walcher D, Aleksic M, Jerg V, Hombach V, Zieske A, Homma S, Strong J, Marx N: C-peptide induces chemotaxis of human CD4-positive cells – involvement of pertussis toxin-sensitive G-proteins and PI 3-kinase. Diabetes 2004; 53:1664-1670
  • Marx N, Walcher D, Ivanova N, Rautzenberg K, Jung A, Friedl R, Hombach V, de Caterina R, Basta G, Wautier MP, Wautier JL: Thiazolidinediones reduce endothelial expression of receptors for advanced glycation endproducts (RAGEs). Diabetes 2004; 53:2662-2668
  • Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, Konrad T, Forst T:Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005; 45(12):1925-31.
  • Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Häring H.-U., Koenig W, Marx N: Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscl Thromb Vasc Biol 2005; 25:1804-1809
  • Marx N, Wöhrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Höher M: Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in non-diabetic patients. Circulation 2005; 112:2792-2798
  • Meisner F, Walcher D, Gizard F, Kapfer X, Huber R, Noak A, Sunder-Plassmann L, Bach H, Haug C, Bachem M, Stojakovic T, März W, Hombach V, Koenig W, Staels B, Marx N: Effect of rosiglitazone treatment on plaque inflammation and collagen content in non-diabetic patients - data from a randomized, placebo-controlled trial. Arterioscl Thromb Vasc Biol. 2006; 26:845-850.
  • Walcher D, Kümmel A, Kehrle B, Bach H, Grüb M, Durst R, Hombach V, Marx N: LXR activation reduces proinflammatory cytokine expression in CD4-positive lymphocytes. Arterioscl Thromb Vasc Biol. 2006; 26:1022-1028.
  • Walcher D, Babiak C, Poletek P, Rosenkranz S, Bach H, Betz S, Durst R, Grüb M, Hombach V, Strong J, Marx N: C-peptide induces smooth muscle cell proliferation - involvement of src-kinase, phosphatidylinositol 3-kinase and extracellular signal-regulated kinase ½. Circ Res 2006; 99(11):1181-7
  • Hanefeld M, Marx N, Pfutzner A, Baurecht W, Lubben G, Karagiannis E, Stier U, Forst T.  Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol. 2007; 23;49(3):290-297.
  • Forst T, Pfutzner A, Lubben G, Weber M, Marx N, Karagiannis E, Koehler C, Baurecht W, Hohberg C, Hanefeld M. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism. 2007;56:491-6.
  • Balmforth AJ, Grant PJ, Scott EM, Wheatcroft SB, Kearney MT, Staels B, Marx N. Inter-subject differences in constitutive expression levels of the clock gene in man. Diab Vasc Dis Res. 2007;4(1):39-43.
  • Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G.  PPARgamma Activation Primes Human Monocytes into Alternative M2 Macrophages with Anti-inflammatory Properties. Cell Metab. 2007; 2:137-143
  • Walcher D, Heß K, Heinz P, Petscher K, Vasic D, Kintscher U, Clemenz M, Hartge M, Raps K, Hombach V, Marx N. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via PPARgamma. Hypertension  2008; 51:259-266